Login to Your Account



ASCO 2014

Hutchison Medipharma hopes to break through with Volitinib for papillary renal cell carcinoma

By Shannon Ellis


Wednesday, May 28, 2014

SHANGHAI – Hutchison Medipharma Ltd. (HMP) is set to turn a corner announcing strong early results for not one, but three of its oncology drugs at ASCO 2014 this weekend in Chicago. Arguably the most exciting is the phase I data for Volitinib, a c-Met inhibitor that has shown strong results on patients with papillary renal cell carcinoma (PRCC), a rare form of cancer with no existing treatment.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription